The Imugene share price has continued its slide and is down a further 6% to 16.5 cents. This means that the biotech company's shares are now down over 60% since the start of the year. Valuation concerns have been weighing on its shares. There may also be fears that this trend could continue given its market capitalisation of almost $1 billion and no revenue.